Drug Trial Radar · NCT07473843
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Jul 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of zodasiran subcutaneous (sc) injection in participants 12 to \<18 years of age with genetically or clinically diagnosed homozygous familial hypercholesterolemia (HoFH) and low-density lipoprotein cholesterol (LDL-C) ≥116 milligrams per deciliter (mg/dL) on maximally tolerated lipid-lowering therapy.
Conditions
- Homozygous Familial Hypercholesterolemia
Interventions
ZodasiranDrug
By sc injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline to Month 12 in Fasting LDL-CTime frame: Baseline, Month 12
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
St Louis, Missouri · Recruiting
Research Site
Viborg, Denmark · Recruiting
Research Site
Warsaw, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.